iRadimed Corporation $IRMD Shares Sold by Isthmus Partners LLC

Isthmus Partners LLC lessened its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 49.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,693 shares of the medical equipment provider’s stock after selling 24,918 shares during the period. Isthmus Partners LLC’s holdings in iRadimed were worth $2,473,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of IRMD. Royal Bank of Canada increased its position in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after purchasing an additional 3,307 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of iRadimed by 7.5% during the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 1,108 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after buying an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after buying an additional 1,821 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on IRMD. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $120.00.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 40,000 shares of company stock worth $3,562,103. 34.60% of the stock is owned by corporate insiders.

iRadimed Stock Down 3.9%

IRMD opened at $96.31 on Thursday. iRadimed Corporation has a 52 week low of $55.11 and a 52 week high of $107.90. The business has a fifty day simple moving average of $91.70 and a 200-day simple moving average of $95.98. The firm has a market cap of $1.23 billion, a P/E ratio of 52.63 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts expect that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were issued a $0.20 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s payout ratio is 43.72%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.